UA112970C2 - Інактивований вірус вітряної віспи, спосіб його одержання і застосування - Google Patents

Інактивований вірус вітряної віспи, спосіб його одержання і застосування

Info

Publication number
UA112970C2
UA112970C2 UAA201302742A UAA201302742A UA112970C2 UA 112970 C2 UA112970 C2 UA 112970C2 UA A201302742 A UAA201302742 A UA A201302742A UA A201302742 A UAA201302742 A UA A201302742A UA 112970 C2 UA112970 C2 UA 112970C2
Authority
UA
Ukraine
Prior art keywords
receiving
application
vzv
virus
island virus
Prior art date
Application number
UAA201302742A
Other languages
English (en)
Inventor
Девід Л. Крах
Джилл ДЕХАВЕН
Дженніфер А. Крісс
Коллін М. Барр
Мері Ягодіч
Original Assignee
Мерк Шарп Енд Доме Корп.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Мерк Шарп Енд Доме Корп. filed Critical Мерк Шарп Енд Доме Корп.
Publication of UA112970C2 publication Critical patent/UA112970C2/uk

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/245—Herpetoviridae, e.g. herpes simplex virus
    • A61K39/25—Varicella-zoster virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N13/00—Treatment of microorganisms or enzymes with electrical or wave energy, e.g. magnetism, sonic waves
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C12N7/04—Inactivation or attenuation; Producing viral sub-units
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5252—Virus inactivated (killed)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16711—Varicellovirus, e.g. human herpesvirus 3, Varicella Zoster, pseudorabies
    • C12N2710/16734—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16711—Varicellovirus, e.g. human herpesvirus 3, Varicella Zoster, pseudorabies
    • C12N2710/16761—Methods of inactivation or attenuation

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Mycology (AREA)
  • Biotechnology (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

Винахід стосується інактивованого вірусу вітряної віспи (VZV), який підходить для введення пацієнту з ослабленим імунітетом у вакцині проти VZV, де VZV інактивований з використанням від 10 до 25 кГр гамма-опромінення, де інфекційність VZV складає ≤0,040 бляшкоутворювальних одиниць (БУО)/мл, фармацевтичної композиції, яка містить вказаний інактивований вірус, та її застосування для лікування оперізувального лишаю.
UAA201302742A 2010-08-05 2011-04-08 Інактивований вірус вітряної віспи, спосіб його одержання і застосування UA112970C2 (uk)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US37103810P 2010-08-05 2010-08-05
PCT/US2011/046534 WO2012018973A1 (en) 2010-08-05 2011-08-04 Inactivated varicella zoster virus vaccines, methods of production, and uses thereof

Publications (1)

Publication Number Publication Date
UA112970C2 true UA112970C2 (uk) 2016-11-25

Family

ID=45556327

Family Applications (1)

Application Number Title Priority Date Filing Date
UAA201302742A UA112970C2 (uk) 2010-08-05 2011-04-08 Інактивований вірус вітряної віспи, спосіб його одержання і застосування

Country Status (23)

Country Link
US (3) US20120034267A1 (uk)
EP (2) EP2600893A4 (uk)
JP (2) JP2013535488A (uk)
KR (3) KR20130036062A (uk)
CN (1) CN103167880B (uk)
AR (1) AR082577A1 (uk)
AU (1) AU2011285749B2 (uk)
BR (1) BR112013001946A2 (uk)
CA (1) CA2806454A1 (uk)
CL (2) CL2013000360A1 (uk)
CO (1) CO6731067A2 (uk)
EC (1) ECSP13012476A (uk)
MX (1) MX343600B (uk)
MY (1) MY158419A (uk)
NZ (1) NZ606549A (uk)
PE (1) PE20131336A1 (uk)
PH (1) PH12013500133A1 (uk)
RU (1) RU2633058C2 (uk)
SG (1) SG187222A1 (uk)
TW (1) TW201208698A (uk)
UA (1) UA112970C2 (uk)
WO (1) WO2012018973A1 (uk)
ZA (1) ZA201300622B (uk)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015034807A2 (en) 2013-09-05 2015-03-12 Merck Sharp & Dohme Corp. Methods of immunization with varicella zoster virus antigen
RU2651040C2 (ru) * 2016-08-08 2018-04-18 Федеральное государственное бюджетное учреждение "48 Центральный научно-исследовательский институт" Министерства обороны Российской Федерации Вакцина оспенная инактивированная эмбриональная сухая таблетированная для орального применения "ТЭОВин" и способ ее получения
RU2637093C1 (ru) * 2016-12-20 2017-11-29 Федеральное государственное бюджетное научное учреждение "Научно-исследовательский институт вакцин и сывороток им. И.И. Мечникова" (ФГБНУ НИИВС им. И.И. Мечникова) Способ получения живой культуральной аттенуированной вакцины для профилактики ветряной оспы
CN107174658B (zh) * 2017-04-29 2020-11-27 安徽智飞龙科马生物制药有限公司 人用水痘病毒灭活疫苗及其制备方法
CN109453371A (zh) * 2018-11-23 2019-03-12 中国兽医药品监察所 一种羊痘、山羊传染性胸膜肺炎二联灭活疫苗及其生产方法
RU2700410C1 (ru) * 2019-05-20 2019-09-17 Федеральное государственное бюджетное учреждение науки "Национальный научный центр морской биологии им. А.В. Жирмунского" Дальневосточного отделения Российской академии наук (ННЦМБ ДВО РАН) Метод иммуноокрашивания биологического материала для конфокальной микроскопии
CA3158539A1 (en) 2019-12-16 2021-06-24 Johanna Jacoba Elisabeth Bijlsma Inactivated piscine orthoreovirus vaccine
WO2024191324A1 (ru) * 2023-03-13 2024-09-19 Олег Александрович ШИЛОВ Способ получения препарата вакцины из цельных вирусов или бактерий

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5341202B2 (uk) 1974-03-12 1978-11-01
DE2714665A1 (de) * 1977-04-01 1978-10-05 Mayr Anton Praeparat zur behandlung von herpes zoster und anderen herpes-infektionen, sowie verfahren zu seiner herstellung
WO1994002596A1 (en) * 1992-07-17 1994-02-03 Merck & Co., Inc. Method for preventing zoster or alleviating varicella related post-herpetic neuralgia
US6022876A (en) * 1996-11-15 2000-02-08 Yale University L-β-dioxolane uridine analogs and methods for treating and preventing Epstein-Barr virus infections
GB9921146D0 (en) * 1999-09-07 1999-11-10 Smithkline Beecham Biolog Novel composition
WO2001087357A2 (en) * 2000-05-17 2001-11-22 The American National Red Cross Gamma irradiation of protein-based pharmaceutical products
US6946098B2 (en) * 2001-08-10 2005-09-20 Clearant, Inc. Methods for sterilizing biological materials
US20050175630A1 (en) * 2003-12-23 2005-08-11 Eyal Raz Immunogenic compositions and methods of use thereof
EP1721981A4 (en) * 2004-03-05 2007-03-14 Univ Osaka Res Found RECOMBINANT VARICELLA ZOSTER VIRUS
GB0504436D0 (en) * 2005-03-03 2005-04-06 Glaxosmithkline Biolog Sa Vaccine
RU2011107757A (ru) 2008-08-01 2012-09-10 Гамма Ваксинс Пти Лимитед (Au) Вакцины против гриппа

Also Published As

Publication number Publication date
MX2013001434A (es) 2013-03-12
JP2016053032A (ja) 2016-04-14
EP2600893A1 (en) 2013-06-12
AR082577A1 (es) 2012-12-19
RU2013109417A (ru) 2014-09-10
ZA201300622B (en) 2013-09-25
PH12013500133A1 (en) 2013-03-11
US20180318412A1 (en) 2018-11-08
CN103167880B (zh) 2016-05-18
PE20131336A1 (es) 2013-11-21
WO2012018973A1 (en) 2012-02-09
CL2016003181A1 (es) 2017-06-02
SG187222A1 (en) 2013-03-28
MX343600B (es) 2016-11-10
BR112013001946A2 (pt) 2016-05-24
US20150209424A1 (en) 2015-07-30
AU2011285749A1 (en) 2013-01-31
RU2633058C2 (ru) 2017-10-11
AU2011285749B2 (en) 2014-07-31
MY158419A (en) 2016-10-14
EP3363894A1 (en) 2018-08-22
US20120034267A1 (en) 2012-02-09
KR20130036062A (ko) 2013-04-09
NZ606549A (en) 2014-12-24
JP2013535488A (ja) 2013-09-12
CL2013000360A1 (es) 2014-03-28
TW201208698A (en) 2012-03-01
EP2600893A4 (en) 2014-01-22
CN103167880A (zh) 2013-06-19
KR20160060790A (ko) 2016-05-30
CO6731067A2 (es) 2013-08-15
ECSP13012476A (es) 2013-04-30
CA2806454A1 (en) 2012-02-09
KR20160018828A (ko) 2016-02-17

Similar Documents

Publication Publication Date Title
UA112970C2 (uk) Інактивований вірус вітряної віспи, спосіб його одержання і застосування
CY1117673T1 (el) Ανασυνδυασμενα αντιγονα rsv
BR112017005111A2 (pt) compostos, composição farmacêutica, usos de um composto ou de um sal farmaceuticamente aceitável do mesmo para o tratamento de um hospedeiro infectado com um papilomavírus humano, usos de um composto, método para a fabricação de um medicamento destinado ao uso terapêutico para o tratamento de uma infecção por papilomavírus
PE20151867A1 (es) Polipeptidos f de prefusion del virus sincicial respiratorio (rsv )solubles y estabilizados
MX376691B (es) Composición farmaceutica que comprende un antagonista de il-4r para tratar una infección cutánea.
EA201290131A1 (ru) Производные пурина или деазапурина для применения при лечении вирусных инфекций и других заболеваний
MX2015008009A (es) Compuestos de carbamoilpiridona policiclicos y su uso farmaceutico.
MX2016004492A (es) Inhibidores de la replicacion del virus de inmunodeficiencia humana (vih).
UA116999C2 (uk) Виділене антитіло до гемаглютиніну та фармацевтична композиція, що його містить
MX2011013296A (es) Metodos de tratamiento o prevención de enfermedad asociada a influenza con soluciones acuosas con potencial de oxidación-reduccion.
PH12014500466A1 (en) Hpv chimaeric particle
MX2017003117A (es) Particula tipo virus de flavivirus.
EP4272839A3 (en) Treatment of allergic rhinitis using a combination of mometasone and olopatadine
CY1120158T1 (el) Γλουταρυλο ισταμινη για την αγωγη και προφυλαξη παθησεων προκαλουμενων απο ιους που περιεχουν (+)rna
PH12016500465B1 (en) Deoxynojirimycin derivatives and methods of their using
BR112022000971A2 (pt) Derivados de di-hidropirimidina e uso dos mesmos no tratamento de infecção por hbv ou de doenças induzidas por hbv
PE20110327A1 (es) Vacuna contra el virus de papiloma humano
IL182440A0 (en) Subtype-matched inactivated whole virus vaccines for treating patients with hiv infection
MX2013003245A (es) Vacuna contra virus de diarrea viral de bovinos.
SG10201908089VA (en) Novel dosing regimens of celgosivir for the treatment of dengue
WO2013173256A3 (en) New and improved influenza vaccines
EA201390925A1 (ru) Производные санглиферина и способы их получения
BR112022000944A2 (pt) Derivados de di-hidropirimidina e seus usos no tratamento de infecção por hbv ou de doenças induzidas por hbv
BR112022001564A2 (pt) Derivados de di-hidropirimidina e seus usos no tratamento de infecção por hbv ou de doenças induzidas por hbv
PH12017500928A1 (en) A rabies composition comprising pika adjuvant